信隆健康: 半年报监事会决议公告

Group 1 - The core point of the announcement is the approval of the company's 2025 semi-annual report and the decision to repurchase and cancel certain restricted stocks due to unmet performance targets [1][2][3] - The meeting of the supervisory board was held on August 21, 2025, with all three supervisors present, and the resolutions were passed unanimously [1] - The company plans to repurchase a total of 1,818,050 shares, which includes 75,000 shares from three original incentive recipients and 1,743,050 shares due to unmet performance conditions [6][7] Group 2 - The adjusted repurchase price for the restricted stocks is set at 3.49 yuan per share, plus interest from bank deposits [2][3] - The company will reduce its total shares from 368,060,000 to 366,241,950 and its registered capital accordingly [6][7] - The supervisory board has agreed to abolish the supervisory board and its positions, transferring the responsibilities to the audit committee of the board of directors, pending approval from the shareholders' meeting [7]